Future of Pre- and Probiotics to be Discussed by Kibow Biotech Founder During SupplySide MarketPlace 2013 Global Expo & Conference
Published: Apr 29, 2013
NEWTOWN SQUARE, Pa., April 29, 2013 /PRNewswire/ -- Dr. Natarajan Ranganathan, one of the founders and the managing director for R&D and Operations of Kibow Biotech, Inc., has been invited to deliver a talk as a part of an educational seminar on "Pre- & Probiotics Market, Science, Regulations and Applications" at the upcoming SupplySide MarketPlace 2013 Global Expo & Conference.
The educational seminar will be held at the Jacob Javits Convention Center in New York City on Tuesday, April 30 and Wednesday, May 1, 2013 and will cover some basic and fundamental topics, as well as state-of-the-art issues. Twelve experts from R&D, marketing, regulatory and clinical areas of the industry will come together at this course to share their respective knowledge and professional expertise.
Dr. Ranganathan's speech "Probiotics, Prebiotics, and Synbiotics: Gut and Beyond Futuristic Potential Health Applications" will provide an overview of the novel science and the technological applications in the rapidly emerging field of probiotics, and his vision for the future of the industry. He will also share his experiences as an entrepreneur and scientist, having led the effort that resulted in the development of Renadyl, a scientifically formulated and clinically tested, patented and proprietary probiotic dietary supplement designed specifically to help maintain healthy kidney function.
Dr. Ranganathan stated, "We were previously honored to have been chosen to present our 'Enteric Toxin Reduction' technology, at the time still in development, in one of the 20 selected posters at the 'Global Innovation Corridor' session of BIO-2007 Boston event. This year, we are excited to have the opportunity to present at Global Expo & Conference Supply Side East as a rapidly developing, revenue-generating, mid-stage biotech company."
About the Global Expo & Conference Smart Short Courses:
The educational seminar will cover various aspects of the emerging global field of pre- and probiotics, which is projected to exceed $20 billion by 2015, a 13% growth rate. As recent research indicates, probiotics are implicated in a number of widely prevalent health conditions, and thus have the potential to become one of the leading functional food categories in the global market. Much depends upon the critical process of microorganism selection, the availability of stable delivery systems and clinical validation for its intended application. In the last decade progressively more consumers have become aware of and familiar with probiotics and their functions.
About Kibow Biotech
Founded in 1997, Kibow Biotech specializes in research and development of probiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl, is currently marketed via on-line sales in the U.S. and Canada, progressively becoming available worldwide, in accordance with individual countries' rules and regulations. Renadyl utilizes "enteric toxin reduction technology" to address the accumulation of toxins in the bowel as a consequence of reduced kidney function.
About Enteric Toxin Reduction Technology
Kibow's novel technology addresses the diffusion of various uremic toxins into the bowel as a consequence of the failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl (human formulation) and Azodyl® (veterinary formulation exclusively distributed and marketed worldwide by Vetoquinol-USA), consist of different concentrations of three specific probiotic microbial strains. The results of the 2010 randomized, double blind, crossover, pilot scale human clinical trial, as well as two additional 6-month trials concluded recently, have provided encouraging preliminary evidence that the Company's technology could be effective when the formulation is taken together with the standard therapy appropriate to individual kidney problems.
This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Renadyl. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
For further information, contact:
Natarajan Ranganathan, Ph.D.,
Managing Director (R&D)
1 (610) 353-5130
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.